Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia

G. Barosi, L. N. Liberato, R. Guarnone

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Serum erythropoietin levels (s-Epo) were measured by radioimmunoassay in 61 consecutive anaemic patients (Hb <12 g/dl) with myelofibrosis with myeloid metaplasia (MMM). S-Epo was inversely correlated with Hb (r = -0.48, P <0.0001). When observed s-Epo values were compared with predicted levels based on the relationship between s-Epo and Hb in control subjects, all but eight patients (87%) had s-Epo levels appropriate for the degree of anaemia. The observed/predicted (O/P) s-Epo ratio was significantly lower in patients with signs of active disease, and a significant inverse correlation was found between the O/P ratio and erythrokinetic measurement of the extent of erythropoiesis (r = 0.31; P = 0.02). Circulating Epo levels were appropriate for the variations in Hb during the postsplenectomy period in three patients. In conclusion, this study does not support the idea that therapy with erythropoietin should be extensively used in anaemic patients with MMM, but rather that it should be considered only in selected cases.

Original languageEnglish
Pages (from-to)365-369
Number of pages5
JournalBritish Journal of Haematology
Volume83
Issue number3
Publication statusPublished - 1993

Fingerprint

Primary Myelofibrosis
Erythropoietin
Serum
Erythropoiesis
Radioimmunoassay
Anemia

ASJC Scopus subject areas

  • Hematology

Cite this

Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia. / Barosi, G.; Liberato, L. N.; Guarnone, R.

In: British Journal of Haematology, Vol. 83, No. 3, 1993, p. 365-369.

Research output: Contribution to journalArticle

@article{55c04642c5954324a8e08358abbdb9dc,
title = "Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia",
abstract = "Serum erythropoietin levels (s-Epo) were measured by radioimmunoassay in 61 consecutive anaemic patients (Hb <12 g/dl) with myelofibrosis with myeloid metaplasia (MMM). S-Epo was inversely correlated with Hb (r = -0.48, P <0.0001). When observed s-Epo values were compared with predicted levels based on the relationship between s-Epo and Hb in control subjects, all but eight patients (87{\%}) had s-Epo levels appropriate for the degree of anaemia. The observed/predicted (O/P) s-Epo ratio was significantly lower in patients with signs of active disease, and a significant inverse correlation was found between the O/P ratio and erythrokinetic measurement of the extent of erythropoiesis (r = 0.31; P = 0.02). Circulating Epo levels were appropriate for the variations in Hb during the postsplenectomy period in three patients. In conclusion, this study does not support the idea that therapy with erythropoietin should be extensively used in anaemic patients with MMM, but rather that it should be considered only in selected cases.",
author = "G. Barosi and Liberato, {L. N.} and R. Guarnone",
year = "1993",
language = "English",
volume = "83",
pages = "365--369",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "3",

}

TY - JOUR

T1 - Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia

AU - Barosi, G.

AU - Liberato, L. N.

AU - Guarnone, R.

PY - 1993

Y1 - 1993

N2 - Serum erythropoietin levels (s-Epo) were measured by radioimmunoassay in 61 consecutive anaemic patients (Hb <12 g/dl) with myelofibrosis with myeloid metaplasia (MMM). S-Epo was inversely correlated with Hb (r = -0.48, P <0.0001). When observed s-Epo values were compared with predicted levels based on the relationship between s-Epo and Hb in control subjects, all but eight patients (87%) had s-Epo levels appropriate for the degree of anaemia. The observed/predicted (O/P) s-Epo ratio was significantly lower in patients with signs of active disease, and a significant inverse correlation was found between the O/P ratio and erythrokinetic measurement of the extent of erythropoiesis (r = 0.31; P = 0.02). Circulating Epo levels were appropriate for the variations in Hb during the postsplenectomy period in three patients. In conclusion, this study does not support the idea that therapy with erythropoietin should be extensively used in anaemic patients with MMM, but rather that it should be considered only in selected cases.

AB - Serum erythropoietin levels (s-Epo) were measured by radioimmunoassay in 61 consecutive anaemic patients (Hb <12 g/dl) with myelofibrosis with myeloid metaplasia (MMM). S-Epo was inversely correlated with Hb (r = -0.48, P <0.0001). When observed s-Epo values were compared with predicted levels based on the relationship between s-Epo and Hb in control subjects, all but eight patients (87%) had s-Epo levels appropriate for the degree of anaemia. The observed/predicted (O/P) s-Epo ratio was significantly lower in patients with signs of active disease, and a significant inverse correlation was found between the O/P ratio and erythrokinetic measurement of the extent of erythropoiesis (r = 0.31; P = 0.02). Circulating Epo levels were appropriate for the variations in Hb during the postsplenectomy period in three patients. In conclusion, this study does not support the idea that therapy with erythropoietin should be extensively used in anaemic patients with MMM, but rather that it should be considered only in selected cases.

UR - http://www.scopus.com/inward/record.url?scp=0027399747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027399747&partnerID=8YFLogxK

M3 - Article

C2 - 8485043

AN - SCOPUS:0027399747

VL - 83

SP - 365

EP - 369

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -